A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells

The outlook for patients with refractory/relapsed acute myeloid leukemia (AML) remains poor, with conventional chemotherapeutic treatments often associated with unacceptable toxicities, including severe infections due to profound myelosuppression. Thus there exists an urgent need for more effective...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Kovtun, Yelena, Jones, Gregory E., Adams, Sharlene, Harvey, Lauren, Audette, Charlene A., Wilhelm, Alan, Bai, Chen, Rui, Lingyun, Laleau, Rassol, Liu, Fenghua, Ab, Olga, Setiady, Yulius, Yoder, Nicholas C., Goldmacher, Victor S., Chari, Ravi V. J., Pinkas, Jan, Chittenden, Thomas
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2018
Soggetti:
Myeloid Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5916008/
https://ncbi.nlm.nih.gov/pubmed/29661755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018017517
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi